Influenza virus resistance to neuraminidase inhibitors

Drug Resistance Updates

Volumn 1, Issue 3, 1998, Pages 184-189

  Mendel, Dirk B ^a   Sidwell, Robert W ^b  

^a GILEAD SCIENCES   (United States)

^b UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001603941     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80038-1     Document Type: Review

References (43)

1. Monto A.S., Iacuzio I.A., and LaMontague J.R. Pandemic influenza-confronting a reemergent threat. J Infect Dis 176 Suppl I (1997) 51-53
2. Hayden F.G., and Couch R.B. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. Rev Med Virol 2 (1992) 89-96
3. Monto A.S., and Arden N.H. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis 15 (1992) 362-367
4. Palese P., and Compans R.W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 33 (1976) 159-163
5. Liu C., Eichelberger M.C., Compans R.W., and Air G.M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly or budding. J Virol 69 (1995) 1099-1106
6. Colman P.M. Neuraminidase: Enzyme and antigen. In: Krug R.M. (Ed). The Influenza Viruses (1989), Plenum, New York 175-218
7. Colman P.M., Hoyne P.A., and Lawrence M.C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 67 (1993) 2972-2980
8. Colman P.M. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3 (1994) 1687-1696
9. Varghese J.N., McKimm-Breschkin J.L., Caldwell J.B., et al. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14 (1992) 327-332
10. Burmeister W.P., Ruigrok R.W., and Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 11 (1992) 49-56
11. von Itzstein M., Wu W.-Y., Kok G.B., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993) 418-423
12. Li W., Escarpe P.A., Eisenburg E.J., et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42 (1998) 647-653
13. Kim C.U., Lew W., Williams M.A., et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Amer Chem Soc 119 (1997) 681-690
14. Woods J.M., Bethell R.C., Coates J., et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents and Chemother 37 (1993) 1473-1479
15. Thomas G.P., Forsyth M., Penn C.R., and McCauley J.W. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res 24 (1994) 351-356
16. Hayden F.G., Rollins B.S., and Madren L.K. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 25 (1994) 123-131
17. Mendel D.B., Tai C.Y., Escarpe P.A., et al. Oral administration of a prodrug of the influenza neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42 (1998) 640-646
18. Ryan D.M., Ticehurst J., Dempsey M.H., and Penn C.R. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 38 (1994) 2270-2275
19. Ryan D.M., Ticehurst J., and Dempsey M.H. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 39 (1995) 2583-2584
20. Sidwell R.W., Huffman J.H., Barnard D.L., et al. Inhibition of influenza A virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 37 (1998) 107-120
21. Hayden F.G., Treanor J.J., Betts A.F., et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J Amer Med Assoc 275 (1996) 295-299
22. Hayden F.G., Osterhaus A., Treanor J.J., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New Engl J Med 337 (1997) 874-880
23. LB-26 abstract. Hayden F.G., Lobo M., Treanor J.J., et al. Efficacy and tolerability of oral GS 4104 for early treatment of experimental influenza in humans. Program and Abstracts of the 37th ICAAC. Toronto, Ontario, Canada: September 28-October 1 (1997)
24. Oxford J.S., Logan I.S., and Potter C.W. Passage of influenza strains in the presence of aminoadamantane. Ann NY Acad Sci 173 (1970) 300-313
25. Gubareva L.V., Bethell R., Hart G.J., et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 70 (1996) 1818-1827
26. Gubareva L.V., Robinson M.J., Bethell R.C., and Webster R.G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 71 (1997) 3385-3390
27. McKimm-Breschkin J.L., Blick T.J., Sahasrabudhe A., et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 40 (1996) 40-46
28. Penn C.R., Barnett J.M., Bethell R.C., et al. Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in haemagglutinin may compensate for loss of neuraminidase activity. In: Brown L.E., Hampson A.W., and Webster R.G. (Eds). Options for the control of influenza III (1996), Elsevier, Amsterdam 735-740
29. Staschke K.A., Colacino J.M., Baxter A.J., et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214 (1995) 642-646
30. McKimm-Breschkin J.L., Sahasrabudhe A., Blick T.J., et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 72 (1998) 2456-2462
31. Sahasrabudhe A., Blick T., and McKimm-Breschkin J. Influenza virus variants resistant to GG167 with mutations in the haemagglutinin. In: Brown L.E., Hampson A.W., and Webster R.G. (Eds). Options for the control of influenza III (1996), Elsevier, Amsterdam 748-752
32. abstract. Hayden F.G., and Rollins B.S. In vitro activity of the neuraminidase inhibitor GS4071 against influenza viruses. Antiviral Res 34 (1997) A86
33. Blick T.J., Tiong T., Sahasrabudhe A., et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 214 (1995) 475-484
34. Varghese J.N., Epa V.C., and Colman P.M. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 4 (1995) 1081-1087
35. Goto H., Bethell R.C., and Kawaoka Y. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 238 (1997) 265-272
36. Colacino J.M., Chirgadze N.Y., Garman E., et al. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 236 (1997) 66-75
37. McKimm-Breschkin J.L., McDonald M., Blick T.J., and Colman P.M. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 225 (1996) 240-242
38. Colacino J.M., Laver W.G., and Air G.M. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J Infect Dis 176 Suppl I (1997) S66-S68
39. abstract. Mendel D.B., Tai C.Y., and Escarpe P.A. In vitro selection and characterization of a human influenza virus with decreased susceptibility to GS 4071. Antiviral Res 37 (1998) A71
40. Smith P.W., Sollis S.L., Howes P.D., et al. Novel inhibitors of influenza sialidases related to GG167 Structure-activity, crystallographic and molecular dynamic studies with 4H-pyran-2-carboxylic acid 6-carboxamides. Bioorg Med Chem Lett 6 (1996) 2931-2936
41. Huffman J.H., Sidwell R.W., Barnard D.L., et al. Influenza virus-inhibitory effects of a series of germanium- and silicon-centred polyoxometalates. Antiviral Chem Chemother 8 (1997) 75-83
42. Sidwell R.W., Huffman J.H., Call E.W., et al. Effect of selenazofurin on influenza A and B virus infections of mice. Antiviral Res 6 (1986) 343-353
43. abstract. Sidwell R.W., Bailey K.W., Wong M.H., et al. Rapid in vivo development of influenza A (H3N2) virus resistance to amantadine and rimantadine. Antiviral Res 3 (1995) A348